Antineoplastic Agents

"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000970
MeSH Number(s)	D27.505.954.248
Concept/Terms	Antineoplastic Agents Antineoplastic Agents Agents, Antineoplastic Antineoplastic Drugs Drugs, Antineoplastic Antineoplastics Chemotherapeutic Anticancer Drug Drug, Chemotherapeutic Anticancer Antitumor Drugs Drugs, Antitumor Cancer Chemotherapy Agents Agents, Cancer Chemotherapy Chemotherapy Agents, Cancer Cancer Chemotherapy Drugs Chemotherapy Drugs, Cancer Drugs, Cancer Chemotherapy Chemotherapeutic Anticancer Agents Agents, Chemotherapeutic Anticancer Anticancer Agents Agents, Anticancer Antitumor Agents Agents, Antitumor

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.

Bar chart showing 439 publications over 28 distinct years, with a maximum of 36 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	2	0	2
1995	2	0	2
1996	1	0	1
1997	4	2	6
1998	4	2	6
1999	6	1	7
2000	3	1	4
2001	7	0	7
2002	7	5	12
2003	7	1	8
2004	7	3	10
2005	9	2	11
2006	9	5	14
2007	10	3	13
2008	14	2	16
2009	16	5	21
2010	15	8	23
2011	22	12	34
2012	14	6	20
2013	21	10	31
2014	22	5	27
2015	23	7	30
2016	29	7	36
2017	17	7	24
2018	24	7	31
2019	17	4	21
2020	14	3	17
2021	4	1	5

Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.

Vranic S, Gatalica Z. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. Bosn J Basic Med Sci. 2022 Feb 01; 22(1):14-21.

View in: PubMed
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.

View in: PubMed
Misek SA, Newbury PA, Chekalin E, Paithankar S, Doseff AI, Chen B, Gallo KA, Neubig RR. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells. Mol Pharmacol. 2022 01; 101(1):1-12.

View in: PubMed
Li Y, VanOsdol J, Ranjan A, Liu C. A multilayer network-enabled ultrasonic image series analysis approach for online cancer drug delivery monitoring. Comput Methods Programs Biomed. 2022 Jan; 213:106505.

View in: PubMed
Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release. 2021 12 10; 340:1-34.

View in: PubMed
MacCuaig WM, Fouts BL, McNally MW, Grizzle WE, Chuong P, Samykutty A, Mukherjee P, Li M, Jasinski JB, Behkam B, McNally LR. Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Appl Mater Interfaces. 2021 Oct 27; 13(42):49614-49630.

View in: PubMed
Wenzel L, Huang HQ, Cella D, McKinney CO, Zevon MA, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, von Gruenigen VE. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021 11; 163(2):392-397.

View in: PubMed
Zaki MM, Mashouf LA, Woodward E, Langat P, Gupta S, Dunn IF, Wen PY, Nahed BV, Bi WL. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep. 2021 09 09; 11(1):18009.

View in: PubMed
Raguraman R, Srivastava A, Munshi A, Ramesh R. Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Adv Drug Deliv Rev. 2021 11; 178:113918.

View in: PubMed
Smith EA, Hill NT, Gelb T, Garman KA, Goncharova EI, Bokesch HR, Kim CK, Wendt KL, Cichewicz RH, Gustafson KR, Brownell I, Henrich CJ. Identification of natural product modulators of Merkel cell carcinoma cell growth and survival. Sci Rep. 2021 06 30; 11(1):13597.

View in: PubMed

People

Explore

Similar Concepts

Top Journals